Relapsing-Remitting MS Facts and Statistics: What You Need to Know

Relapsing-remitting multiple sclerosis (RRMS), the most common type of multiple sclerosis, affects 85% to 90% of people with MS. RRMS is associated with exacerbations (relapses) of new or worsening neurological symptoms followed by periods of symptom recovery (remission).

This article will review key facts and statistics about relapsing-remitting MS, including disease prevalence and how it affects life expectancy. It will also provide insight into the possible causes of RRMS and how it's diagnosed.

Healthcare provider discusses RRMS with person seeking care

Evgeniia Siiankovskaia / Getty Images

Relapsing-Remitting MS Overview

In MS, the immune system attacks the insulating myelin layer of nerve fibers within the brain, spinal cord, and optic nerves. When myelin is damaged, nerve signaling is impaired. This malfunction leads to various symptoms like numbness, fatigue, weakness, and blurry vision.

Most people with MS initially are diagnosed with RRMS. They experience relapses that last at least 24 hours and typically continue for days or weeks before they go away or improve.

As with other types of MS, relapsing-remitting MS cannot be reversed or cured. Periods of remission, however, can be lengthened by taking disease-modifying therapies (DMTs). Also, powerful anti-inflammatory drugs called corticosteroids can shorten relapses.

How Common Is RRMS?

The estimated prevalence of MS in the United States is nearly 1 million adults. RRMS occurs in around 87% of these individuals.

   Estimated U.S. Cases of MS  
 Total MS  1 million  
 RRMS  870,000  

Worldwide, the estimated prevalence of MS is 2.8 million individuals. It has increased from 2.3 million in 2013.

RRMS by Ethnicity

Since 2013, MS prevalence has increased across most ethnicities, including populations within the United States, Middle East, North Africa, Canada, Australia, and Europe. It's unclear whether the increased prevalence is due to improved detection or if environmental factors are at play.

Historically, MS had been most commonly diagnosed in White people of northern European or Scandinavian ancestry. Recent investigation, however, shows a similarity in MS prevalence among both Black and White people.

The finding that MS, including RRMS, is more common in the Black population than previously thought likely indicates that MS has been underrecognized and understudied in Black people, as opposed to being an emerging or rare condition.

RRMS by Age and Gender

RRMS is typically detected in early adulthood, at a median age of 30. About 5% of cases are diagnosed at 50 or older. 

RRMS can manifest in children or adolescents, although only 3%–10% of MS cases occur before age 16. Less than 1% of MS cases manifest before age 10. Most of those with pediatric MS (98%) follow a relapsing-remitting course.

MS is 2 to 3 times more common in females than males across all racial and ethnic groups. Interestingly, females with MS tend to have an earlier onset of disease than males, and they typically show less progression of disability.

Sex Hormones Impact RRMS

Relapsing MS is universally more common in females than males, which supports the idea that the sex hormones estrogen and progesterone may influence disease onset and activity.

Causes of RRMS and Risk Factors

The exact cause of MS, including RRMS, remains unknown. However, it's believed that a complex interplay of genetics, various environmental factors, and abnormal immune system response is involved. By 2021, more than 233 genes had been linked with MS. 

Factors associated with the development of MS include:

Some factors increase a person's chances of having an MS relapse. These factors include infection, stress, low vitamin D levels, and the postpartum period (the time after giving birth).

What Are the Mortality Rates for RRMS?

Research has consistently found a higher mortality rate for people living with relapsing-remitting multiple sclerosis compared to the general population.

What Is the Mortality Rate in MS?

Mortality rate is a measure of the number of deaths during a specific period of time.

For example, one 2017 Norwegian study examining nearly 1,400 people diagnosed with MS over a 60-year time frame had a seven-year shorter lifespan and a nearly threefold higher risk of death than the general population.

Despite the higher mortality rate in MS, people generally live longer than ever, likely due to various improvements in health care and lifestyle habits. Specifically, taking a disease-modifying drug for MS is associated with a lower risk of death compared to receiving no treatment.  

Interestingly, investigators in the 2017 Norwegian study also found that people with RRMS had a six-year longer life expectancy than people with primary progressive MS (PPMS).

PPMS is a relatively rare type of MS associated with slowly worsening symptoms and disability over time in the absence of relapses. The finding suggests that RRMS offers a better outlook than PPMS.

Screening and Early Detection

There is no screening test for RRMS nor a single blood or imaging test that can diagnose RRMS.

To diagnose RRMS, a neurologist (a physician specializing in nervous system disorders) collects data from a person's medical history, neurological exam, and various tests, including:

Individual MS relapses are detected clinically (a person's symptoms) and confirmed by the presence of one or more enhancing lesions (areas of inflammation) on a brain or spinal cord MRI scan.

The neurological symptoms of a relapse last at least 24 hours and do not occur as a result of external factors, like infection or heat.


Nearly 1 million adults in the United States live with multiple sclerosis, and around 85% to 90% have relapsing-remitting MS (RRMS). As the most common type of MS, RRMS is associated with discrete attacks of new or worsening neurological symptoms that improve or go away over time.

RRMS is typically detected in young adulthood and is more common in females. Like other forms of MS, relapsing-remitting is associated with a slightly shorter life span than the general population.

Frequently Asked Questions

  • How common is RRMS?

    RRMS affects 85%–90% of all people with MS, which is around 870,000 adults in the United States.

  • When do people with RRMS develop secondary progressive MS (SPMS)?

    Research suggests that within two decades of RRMS onset, approximately 50% of people will develop SPMS. Secondary progressive MS is characterized by gradually worsening symptoms and disability over time.

  • What is the McDonald criteria for diagnosing RRMS?

    The McDonald criteria is a formal set of guidelines that helps neurologists diagnose relapsing MS accurately and promptly. It requires evidence of damage in at least two distinct parts of their brain/spinal cord/optic nerves at different times.

16 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(1):1–10. doi:10.22074/cellj.2016.4867 (note: doi link not functional, using PMC link)

  2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. doi:10.1177/1352458520970841

  3. Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology. 2022;98(18):e1818-e1827. doi:10.1212/WNL.0000000000200151

  4. McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;2015:817238. doi:10.1155/2015/817238

  5. Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;50:102816. doi:10.1016/j.msard.2021.102816

  6. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27. doi:10.1186/s12883-018-1026-3

  7. Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237–248. doi:10.1177/1756285613488434

  8. Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019;156(1):9-22. doi:10.1111/imm.13004

  9. Goodin DS, Khankhanian P, Gourraud PA, Vince N. The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS One. 2021;16(3):e0246157. doi:10.1371/journal.pone.0246157

  10. Coyle PK. What can we learn from sex differences in MS? J Pers Med. 2021;11(10):1006. doi:10.3390/jpm11101006

  11. Xie Y, Tian Z, Han F, Liang S, Gao Y, Wu D. Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(27):e20885. doi:10.1097/MD.0000000000020885

  12. Lunde HMB, Assmus J, Myhr K-M, Bø L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621–625. doi:10.1136/jnnp-2016-315238

  13. Smyrke N, Dunn N, Murley C, Mason D. Standardized mortality ratios in multiple sclerosis: systematic review with meta-analysis. Acta Neurol Scand. 2022;145(3):360-370. doi:10.1111/ane.13559

  14. Ng HS, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and association with survival. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200005. doi:10.1212/NXI.0000000000200005

  15. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: A reviewJAMA. 2021;325(8):765-779. doi:10.1001/jama.2020.26858

  16. National Multiple Sclerosis Society. Updated McDonald criteria expected to speed the diagnosis of MS and reduce misdiagnosis.

By Colleen Doherty, MD
 Colleen Doherty, MD, is a board-certified internist living with multiple sclerosis.